Jagsonpal Pharmaceuticals Limited

BSE: JAGSNPHARM507789ISIN INE048B01035

Healthcare
Pharmaceuticals
BSE Healthcare

BSE listing

Share price

₹228.00+0.25 (+0.11%)

as of 18 Sep 2026

52W high: ₹264.65
52W low: ₹154.90
Off 52W high: -13.85%
1M return: -0.83%
3M return: +7.37%
6M return: +24.73%
1Y return: -6.40%
20D avg volume: 8,213
50 DMA: ₹232.02
200 DMA: ₹204.57

Key ratios Standalone

Market cap: ₹1,504 Cr
Current price: ₹228.00
52W high / low: ₹264.65 / ₹154.90
Face value: ₹2.00
P/E: 33.00
P/B: 7.62
EPS (TTM): ₹6.91
Book value / share: ₹29.92
ROE: 23.07%
ROCE: 20.30%
Operating margin: 24.41%
Net margin: 16.04%
Debt / equity: 0.00
Net debt: ₹-10.04 Cr
Interest cover: 56.84
Dividend yield: 1.75%
Dividend / share (TTM): ₹4.00
Payout: 57.89%
Cash conversion cycle: 25.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	82.23	64.20	72.94	74.47	75.61	58.56	—
	2.83	3.17	2.98	3.03	2.83	2.77	—
	67.39	55.62	59.32	60.68	64.01	52.41	—
	4.87	2.99	3.95	3.84	5.33	3.48	—
	26.05	19.89	22.81	23.80	22.69	17.50	—
	22.78	15.54	17.58	18.18	19.44	16.57	—
	0.25	0.25	0.26	0.27	0.25	0.26	—
	2.14	2.32	2.39	2.39	2.35	2.31	—
	13.59	13.73	12.64	12.63	15.03	11.56	—
	17.68	11.76	16.60	16.81	14.43	8.92	—
	0.00	0.00	-2.08	0.00	0.00	-0.21	—
	17.68	11.76	14.52	16.81	14.43	8.71	—
	4.49	2.99	3.57	4.24	3.64	2.12	—
	13.19	8.76	10.95	12.57	10.79	6.58	—
	2.00	1.25	1.67	1.88	1.60	0.98	—
Key metrics
	20.07	14.33	17.17	19.47	17.03	11.28	—
	24.40%	22.30%	23.50%	26.10%	22.50%	19.30%	—
	16.00%	13.60%	15.00%	16.90%	14.30%	11.20%	—
	—	4.20%	—	6.40%	—	3.60%	—
	8.80%	9.60%	—	—	—	—	—
	22.20%	33.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	293.84	287.23	268.72	—
	12.01	11.99	8.19	—
	243.01	239.62	226.73	—
	15.65	16.11	18.34	—
	92.55	89.19	80.22	—
	74.08	70.74	70.93	—
	1.03	1.03	0.96	—
	9.24	9.44	8.13	—
	52.59	54.04	50.27	—
	62.85	59.60	50.17	—
	-2.08	-2.08	19.69	—
	60.77	57.52	69.86	—
	15.29	14.44	14.50	—
	45.47	43.08	55.36	—
	6.80	6.40	8.26	—
Key metrics
	71.04	67.99	78.95	—
	24.18%	23.70%	29.40%	—
	15.47%	15.00%	20.60%	—
	—	20.30%	28.10%	—
	—	6.90%	—	—
	—	-22.20%	—	—
	—	46.81	54.95	—
	—	1.09	1.00	—
	—	0.00	0.00	—
	—	-10.04	-11.21	—
	—	25.7	25.3	—
Balance sheet
	—	316.68	278.26	—
	—	143.09	161.19	—
	—	10.04	11.21	—
	—	17.19	13.18	—
	—	14.64	15.20	—
	—	5.07	4.02	—
	—	0.57	0.61	—
	—	11.58	9.73	—
	—	28.30	25.90	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	276.17	239.95	—
Cash flow
	—	46.81	55.30	—
	—	-35.65	-45.15	—
	—	-12.15	-11.70	—
	—	0.00	0.35	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 69.06%

Holder	Type	Holding	Previous	Change
Aresko Progressive Private Limited (Trustee of Aresko Progressive Trust, a in the capacity of representative partner of J&P Investments Partnership)	Promoter	20.26%	—	—
INFINITY CAPITAL (Formerly Infinity Holdings Sidecar1)	Promoter Group	18.06%	—	—
INFINITY HOLDINGS	Promoter Group	16.76%	—	—
INFINITY PORTFOLIO HOLDINGS	Promoter Group	8.69%	—	—
RAJPAL SINGH KOCHHAR	Promoter	4.60%	—	—
MANISH GUPTA	Public	3.08%	—	—
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	1.49%	—	—
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	1.47%	—	—
SANJIV KUMAR DUDEJA	Public	1.41%	—	—
LINCOLN P COELHO	Public	1.18%	—	—
Prithipal Singh Kochhar	Promoter Group	0.41%	—	—
Inderpal Singh Kochhar	Promoter Group	0.28%	—	—
RPSK Strategic LLP	Promoter Group	0.00%	—	—
Aresko Services Limited	Promoter Group	0.00%	—	—
Suvinys Developers Private Ltd	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Summary of Proceedings of 47th Annual General Meeting.18 Sep 2026 · AGM/EGM / AGM
Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting28 Aug 2026 · Company Update / Newspaper Publication
Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-2627 Aug 2026 · AGM/EGM / AGM
BRSR for the Financial year ended March 31, 202627 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual report for Financial Year 2025-2627 Aug 2026 · Others / Reg. 34 (1) Annual Report
Letter providing a web link of annual report 2025-26 to members.27 Aug 2026 · Company Update / General
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 202224 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Newspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18, 202612 Aug 2026 · Company Update / Newspaper Publication
Earning Call Transcript for meeting held on July 30, 20264 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.30 Jul 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 202630 Jul 2026 · Company Update / Newspaper Publication
Change in Senior Management personnel of the Company29 Jul 2026 · Company Update / Change in Management
Corporate Action- Record Date for dividend Purpose: September 04, 202629 Jul 2026 · Corp. Action / Record Date
Intimation for grant of Employee Stock Options29 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Press Release for Unaudited Financial results for quarter ended June 30, 202629 Jul 2026 · Company Update / Press Release / Media Release
Press Release for Unaudited Financial Results for quarter ended June 30, 202629 Jul 2026 · Company Update / Investor Presentation
Unaudited results along with its Limited Review Report for the quarter ended June 30, 202629 Jul 2026 · Result / Financial Results
Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 202629 Jul 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company, as a ....22 Jul 2026 · Company Update / Analyst / Investor Meet
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the unaudited Financial ....22 Jul 2026 · Board Meeting / Board Meeting
Updates on Acquisition of Aequitas Healthcare Private Limited.17 Jul 2026 · Company Update / General
Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.15 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Updates on Acquisition of Aequitas Healthcare Private Limited8 Jul 2026 · Company Update / General
Updates on Acquisition of Aequitas Healthcare Private Limited.7 Jul 2026 · Company Update / General
Compliance Certificate under Reg 74(5) of SEBI(DP) Regulations, 20186 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Press Release on acquisition of Aequitas Healthcare Private Limited.29 Jun 2026 · Company Update / Press Release / Media Release
Acquisition of Aequitas Healthcare Private Limited29 Jun 2026 · Company Update / Acquisition
Closure of Trading window for the quarter ended June 30, 202626 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
press release relating to appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an additional director in the category of Non-Executive Independent Director.25 Jun 2026 · Company Update / Press Release / Media Release
Appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an Additional Director in the category of Non-Executive Independent Director.25 Jun 2026 · Company Update / Change in Management
Appointment of Mr. Anil Kumar Matai (DIN: 03122865) as an Additional Director in the category of Non-Executive Independent Director.25 Jun 2026 · Company Update / Change in Directorate
Allotment of 2,96,320 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.4 Jun 2026 · Company Update / Allotment of ESOP / ESPS
Extinguishment of 16,00,000 Equity Shares of Jagsonpal Pharmaceuticals Limited.2 Jun 2026 · Company Update / Closure of Buy Back
Please find enclosed Annual Secretarial Compliance Report for the Financial Year ended March 31, 202628 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Submission of copy of Post Buy Back Public Advertisement related to Buy back of shares of Company.25 May 2026 · Company Update / Newspaper Publication
Centrum Broking Ltd ("Manager to the Buyback") has submitted to BSE a copy of Post Buyback Public Announcement for the attention of Equity Shareholders / Beneficial Owners of Equity Shares ....25 May 2026 · Company Update / General
Resignation of an Independent Director.18 May 2026 · Company Update / Resignation of Director
Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company7 May 2026 · Company Update / Newspaper Publication
Submission of Letter of Offer for Buy- Back upto 16,00,000 Equity Shares at price of INR-250/- per share amounting to INR-40,00,00,000/-6 May 2026 · Company Update / General
Earning Call Transcript for meeting held on April 28, 20264 May 2026 · Company Update / Earnings Call Transcript

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 4.0000	4 Sep 2026	4 Sep 2026	—
Buy Back of Shares	4 May 2026	4 May 2026	—
Final Dividend - Rs. - 2.5000	12 Sep 2025	12 Sep 2025	—
Stock Split From Rs.5/- to Rs.2/-	8 Jan 2025	8 Jan 2025	—
Final Dividend - Rs. - 5.0000	6 Sep 2024	6 Sep 2024	—

Board meetings

29 Jul 2026 Board Meeting - Financial Results